Fluicell AB (publ) operates as a life science company, provides platforms and research solutions for bioprinting and single-cell biology. The company offers BIOPEN, a microfluidic platform for high-precision single-cell solution delivery that enables to control the cell microenvironment without moving or disturbing the cells; Biozone 6 that generate dose-response curves or study the effects of multiple drug compounds; and Dynaflow Resolve system, an ion channel screening platform, which allows to record various ion channel current in patch-clamp recording configuration. It also provides Biopixlar, a 3D single-cell bioprinting platform that enables high cell viability and cell-to-cell communication; and Biopixlar AER, an easy-to-use 3D bioprinting platform that fits into your fume hood or biosafety cabinet. The company also offers accessory and consumable products for bioprinting and single-cell biology. The company was incorporated in 2012 and is based in Mölndal, Sweden.
Metrics to compare | FLUIC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipFLUICPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.4x | −10.9x | −0.5x | |
PEG Ratio | −0.01 | −0.11 | 0.00 | |
Price/Book | 0.9x | 2.9x | 2.6x | |
Price / LTM Sales | 1.9x | 785.3x | 3.3x | |
Upside (Analyst Target) | - | 0.0% | 43.5% | |
Fair Value Upside | Unlock | −0.7% | 6.8% | Unlock |